Explanation of the standard dosage of Apelix-Piqray and its adjustment principles

Alpelisib (Alpelisib)-Piqray is a selective oral phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor. It is mainly suitable for patients with hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA mutations. It needs to be used in combination with an aromatase inhibitor. The standard dose is usually 300 mg per day, divided into two 150 mg tablets, taken orally at the same time each day with a meal. The dosing regimen is based on long-term international clinical practice standards and is used to maximize efficacy while controlling safety. It is important to note that Apelix must be taken with food to enhance bioavailability and reduce gastrointestinal adverse effects.

During clinical use, dose adjustment strategies are crucial to control side effects. Hyperglycemia is one of the most common adverse reactions of this drug, especially in patients with diabetes or impaired glucose tolerance. Therefore, the patient's basal blood glucose status should be assessed before treatment and dynamically monitored during medication. If the patient experiences mild to moderate hyperglycemia (e.g., fasting blood sugar level is between 160-250 mg/dL), it is usually recommended to continue treatment and start or strengthen anti-hyperglycemia measures; when the blood sugar level exceeds 250 mg/dL, it is recommended to suspend Piqray and take active hypoglycemic treatment until the blood sugar returns to an acceptable range. After that, the medication can be restarted at a lower dose as recommended by the doctor, such as reducing to 250 mg or 200 mg per day. If adverse reactions such as rash, diarrhea, stomatitis, etc. of grade 3 or above occur, it may also be necessary to temporarily interrupt the medication and provide supportive treatment.

In addition, if patients develop severe liver or renal function abnormalities, they should also be evaluated whether to continue taking the drug, and the dose may be reduced based on individual tolerance. If you vomit while taking the medicine, you should not take the medicine again. Continue to take the next dose as planned.

Reference materials:https://www.piqray.com/